Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Australian Clinical LabsASX:ACL -0.83%56 5-Year Yield-on-Cost % is 5.25 as of Jul. 31, 2026, which is 20% above its 10-year median of 4.39. GuruFocus rates ASX:ACL with a GF Score™ of 56/100 and a GF Value™ of A$3.06 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 63 Medical Diagnostics & Research companies, Australian Clinical Labs ranks better than 71.43% on this metric.
The historical rank and industry rank for Australian Clinical Labs's 5-Year Yield-on-Cost % or its related term are showing as below:
ASX:ACL'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.26 Med: 4.39 Max: 21.72
Current: 5.25
During the past 6 years, Australian Clinical Labs's highest Yield on Cost was 21.72. The lowest was 2.26. And the median was 4.39.
ASX:ACL's 5-Year Yield-on-Cost % is ranked better than 71.43% of 63
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.5
vs ASX:ACL: 5.25
Australian Clinical Labs (ASX:ACL) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Australian Clinical Labs 5-Year Yield-on-Cost % Related Terms
ASX:ACL vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Australian Clinical Labs's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Australian Clinical Labs 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Australian Clinical Labs's 5-Year Yield-on-Cost % falls into.
Australian Clinical Labs 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Australian Clinical Labs (ASX:ACL) has a 5-Year Yield-on-Cost % of 5.25 as of Jul. 31, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Australian Clinical Labs and its competitors. This is 20% above median its historical median of 4.39. Over the past decade, Australian Clinical Labs' 5-Year Yield-on-Cost % has ranged from 2.26 to 21.72. According to the industry distribution chart, Australian Clinical Labs ranks #18 out of 63 companies in the Medical Diagnostics & Research industry, placing it in the top 28.6%.
Is Australian Clinical Labs' 5-Year Yield-on-Cost % too high?
Australian Clinical Labs' current 5-Year Yield-on-Cost % of 5.25 is 20% above median its 10-year median of 4.39. Over the past 10 years, this metric has ranged from a low of 2.26 to a high of 21.72. The Medical Diagnostics & Research industry median 5-Year Yield-on-Cost % is 2.50. Australian Clinical Labs' value of 5.25 is 110% above this industry median. Based on the distribution chart, Australian Clinical Labs ranks #18 out of 63 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Australian Clinical Labs has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Australian Clinical Labs' 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Australian Clinical Labs ranks #18 out of 63 companies for 5-Year Yield-on-Cost %. This puts Australian Clinical Labs in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.50. Australian Clinical Labs' value of 5.25 is 110% above this benchmark. Historically, Australian Clinical Labs' own 5-Year Yield-on-Cost % has ranged from 2.26 to 21.72 over the past decade. While the company's 10-year median is 4.39 vs. the industry median of 2.50, Australian Clinical Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.50, based on 63 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Australian Clinical Labs's current 5-Year Yield-on-Cost % of 5.25 is 110% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Australian Clinical Labs and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Australian Clinical Labs's current 5-Year Yield-on-Cost % is 5.25, which is 20% above median its own 10-year median of 4.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australian Clinical Labs stock overvalued right now?
Based on GuruFocus' analysis, Australian Clinical Labs (ASX:ACL) is currently considered Modestly Undervalued. The stock's GF Value™ is A$3.06, compared to a current price of A$2.38 — trading 22.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 5.25, which is 20% above median its 10-year median of 4.39 and 110% above the Medical Diagnostics & Research industry median of 2.50. Australian Clinical Labs' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Australian Clinical Labs (ASX:ACL), the current 5-Year Yield-on-Cost % is 5.25 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?
Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued.
The current stock price of A$2.38 is trading 22.2% below its estimated GF Value™ of A$3.06.
GuruFocus considers Australian Clinical Labs to be Modestly Undervalued.
Key valuation signals for ASX:ACL:
5-Year Yield-on-Cost %: 5.25 (20% above median its 10-year median of 4.39)
GF Value™: A$3.06 vs. price of A$2.38 (22.2% below fair value)
Industry Position: 110% above the Medical Diagnostics & Research median (#18 of 63)
No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
56GF Score
Get the complete analysis for ASX:ACL
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ACL has been successfully added to your 
